In 2018, Crew’s group reported PROTAC-3 as a selective and potent Fak degrader, which can potentially induce the degradation of FAK in human prostate cancer cell line PC3 cells with a DC50 value of 3.0 nM.17 This evidence concerns the gene PTK2 and prostate carcinoma.